加拿大不列颠哥伦比亚省HIV感染者与非感染者带状疱疹发病率的人群研究
该回顾性匹配队列研究基于2000–2019年数据,将9053例启动抗逆转录病毒治疗的HIV感染者与9053例非感染者进行倾向评分匹配。结果显示HIV感染者带状疱疹总体发病率更高,尤其在50岁以下人群,且复发率约为非感染者的两倍;接种疫苗后两组带状疱疹发生率均低且无显著差异。
要点
- HIV感染者带状疱疹风险及复发率均高于非感染者,年轻者风险尤为突出。
- 低CD4计数和病毒载量未抑制与HIV感染者带状疱疹风险独立相关。
- 接种疫苗后带状疱疹发生率低,支持免疫抑制成人扩大接种重组带状疱疹疫苗。
核心结论
- HIV感染者带状疱疹及复发风险仍升高,尤其在年轻或免疫抑制者中;接种疫苗与较低带状疱疹风险相关。
研究设计与样本
- 回顾性、基于人群的匹配队列研究,使用Comparative Outcomes and Service Utilization Trends研究2000–2019年数据。
- 9053例≥19岁启动抗逆转录病毒治疗的HIV感染者经倾向评分匹配至9053例非感染者。
- 通过行政健康记录以12个月洗脱期识别新发带状疱疹。
主要发现
- HIV感染者带状疱疹总体发病率高于非感染者。
- 疫苗可用前,HIV感染者带状疱疹风险显著高于非感染者,尤其<50岁者。
- 2009年后,<50岁HIV感染者风险仍升高,而≥50岁两组风险相似。
- HIV感染者带状疱疹复发频率约为非感染者的两倍。
- HIV感染者中低CD4计数、病毒载量未抑制及部分合并症与较高带状疱疹风险独立相关。
关键数值与推荐
- 接种疫苗后带状疱疹发病率在两组中均低,HIV感染者与非感染者间无有意义差异,突破性事件不常见。
临床怎么用
- 应关注HIV感染者(尤其年轻及免疫抑制者)的带状疱疹风险及复发。
- 支持免疫抑制成人不论年龄扩大接种重组带状疱疹疫苗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Herpes zoster (HZ) incidence is elevated among immunocompromised populations, including people living with HIV (PLWH). We evaluated HZ incidence, associated risk factors, recurrence, and postvaccination HZ occurrence among PLWH compared with people living without HIV (PLWoH) in British Columbia, Canada. METHODS: We conducted a retrospective, population-based matched cohort study using data from the Comparative Outcomes and Service Utilization Trends study (2000-2019). PLWH aged ≥19 years initiating antiretroviral therapy were propensity-score matched to PLWoH from the general population. Incident HZ was identified from administrative health records using a 12-month washout. Age-stratified time-to-event, competing-risk, and multivariable models were used to estimate incidence, risk factors, recurrence, and vaccination-associated outcomes. RESULTS: Among 9053 PLWH and 9053 matched PLWoH, HZ incidence rates were higher among PLWH overall. Before vaccine availability, PLWH experienced substantially higher HZ hazards than PLWoH, particularly among participants aged <50 years. After 2009, HZ risk remained elevated among younger PLWH, while hazards were similar between groups among those aged ≥50 years. HZ recurrence was approximately twice as frequent among PLWH. Among PLWH, advanced immunosuppression, including low CD4 cell counts and unsuppressed viral load, and selected comorbidities were independently associated with higher HZ risk. Postvaccination HZ incidence was low in both populations, with no meaningful difference between PLWH and PLWoH; breakthrough events were uncommon. CONCLUSIONS: PLWH remain at increased risk of HZ and recurrence, especially if younger or immunosuppressed. Vaccination was associated with a lower HZ risk supporting expanded access to recombinant zoster vaccination for immunocompromised adults irrespective of age.
引用
- Lima VD, Hussain SS, Yan J, et al. Incidence of Herpes Zoster Infection (Shingles) Among Adults Living With and Without HIV in British Columbia, Canada: A Population-based Study. J Infect Dis. 2026. PMID: 41805836. doi:10.1093/infdis/jiag118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。